Bicycle Therapeutics plc (NASDAQ:BCYC) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) have received an average recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $44.56.

Several research firms have recently issued reports on BCYC. Royal Bank of Canada initiated coverage on Bicycle Therapeutics in a report on Friday, September 6th. They set an "outperform" rating and a $35.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $55.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday. B. Riley cut shares of Bicycle Therapeutics from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $33.00 to $28.00 in a research report on Wednesday, August 7th. Needham & Company LLC reiterated a "buy" rating and set a $38.00 price target on shares of Bicycle Therapeutics in a research report on Thursday. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th.

Insiders Place Their Bets

In related news, CEO Kevin Lee sold 3,212 shares of the firm's stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total transaction of $71,499.12. Following the completion of the transaction, the chief executive officer now owns 380,864 shares of the company's stock, valued at $8,478,032.64. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders have sold 4,584 shares of company stock worth $102,040. 8.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. GAMMA Investing LLC increased its position in shares of Bicycle Therapeutics by 105.1% during the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company's stock valued at $46,000 after acquiring an additional 1,038 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Bicycle Therapeutics by 69.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company's stock worth $162,000 after purchasing an additional 2,918 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Bicycle Therapeutics by 0.6% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company's stock worth $17,975,000 after purchasing an additional 4,976 shares during the last quarter. Handelsbanken Fonder AB lifted its holdings in shares of Bicycle Therapeutics by 2.4% during the third quarter. Handelsbanken Fonder AB now owns 218,700 shares of the company's stock valued at $4,949,000 after purchasing an additional 5,200 shares in the last quarter. Finally, PNC Financial Services Group Inc. purchased a new stake in shares of Bicycle Therapeutics during the fourth quarter valued at $137,000. 86.15% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Trading Down 0.2 %

Bicycle Therapeutics stock traded down $0.04 during trading hours on Friday, reaching $24.73. The stock had a trading volume of 275,074 shares, compared to its average volume of 352,290. The company has a fifty day simple moving average of $24.06 and a 200-day simple moving average of $23.07. Bicycle Therapeutics has a 52 week low of $12.54 and a 52 week high of $28.67. The stock has a market cap of $1.06 billion, a PE ratio of -5.56 and a beta of 0.89. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.77 and a quick ratio of 14.77.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.10) by $0.33. Bicycle Therapeutics had a negative return on equity of 32.80% and a negative net margin of 417.88%. The company had revenue of $9.36 million for the quarter, compared to the consensus estimate of $6.13 million. The business's quarterly revenue was down 17.9% on a year-over-year basis. Analysts forecast that Bicycle Therapeutics will post -3.17 EPS for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.